Aequus Pharmaceuticals (TSE:AQS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aequus Pharmaceuticals reports a 77.50% increase in revenue for Q3 2024 compared to the previous year, driven by the continued growth of their product Zimed® PF. The company has restructured to reduce costs amidst delayed profitability, while also exploring strategic alternatives to enhance future performance.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.